Small Molecules

24 Mar 2017 Merrimack Initiates Phase 1 Study of MM-310 in Solid Tumors
24 Mar 2017 FDA Approves Symproic® (naldemedine) Once-Daily Tablets C-II for the Treatment of Opioid-Induced Constipation in Adults with Chronic Non-Cancer Pain
23 Mar 2017 Ultragenyx Announces Topline Data from Phase 2 UX007 Glucose Transporter Type-1 Deficiency Syndrome Seizure Study
22 Mar 2017 Cytokinetics Announces Preclinical Data for CK-2127107 Presented at MDA Scientific Conference
22 Mar 2017 AVEO Announces First Patient Dosed in Phase 1/2 TiNivo Trial of Tivozanib and Opdivo® (nivolumab) in Advanced RCC
22 Mar 2017 Akashi Therapeutics Receives FDA Clearance to Resume HT-100 Clinical Development
22 Mar 2017 Galapagos initiates Phase 1 study with novel CF potentiator GLPG3067
22 Mar 2017 FDA Approves Xadago® (Safinamide) for Parkinson’s Disease (PD) Patients
22 Mar 2017 Esperion Announces FDA Confirmation Regarding Regulatory Pathway to Approval for an LDL-C Lowering Indication for Bempedoic Acid
21 Mar 2017 Tarrex Biopharma Announces FDA Acceptance of IND Application for TX803 to Commence Phase I Clinical Trials in Colorectal Cancer Patients
21 Mar 2017 Blueprint Medicines Announces Enrollment of First Patient in Phase 1 Clinical Trial for BLU-667
20 Mar 2017 Jazz Pharmaceuticals Announces Positive Results from the Phase 3 TONES 3 and TONES 4 Studies of JZP-110 in Patients with Obstructive Sleep Apnea
20 Mar 2017 Aevi Genomic Medicine Provides Top-line Results from the SAGA Trial of AEVI-001
20 Mar 2017 Opiant Pharmaceuticals, Inc. Announces Initiation of Phase 2 Clinical Trial Evaluating OPNT001 in Bulimia Nervosa
20 Mar 2017 Neothetics Announces Last Subject Enrolled in Phase 2 Proof of Concept Trial for LIPO-202 for the Reduction of Submental Subcutaneous Fat
20 Mar 2017 Boehringer Ingelheim Phase III study now enrolling patients with progressive fibrosing lung diseases
20 Mar 2017 Lilly Announces Phase 3 MONARCH 2 Breast Cancer Study of Abemaciclib Met Primary Endpoint of Progression-Free Survival
20 Mar 2017 AstraZeneca’s CVD-REAL study shows SGLT-2 inhibitors significantly reduced death and hospitalisations for heart failure versus other type-2 diabetes medicines
20 Mar 2017 Bayer’s Rivaroxaban Demonstrated Superior Protection Against Recurrent Venous Thromboembolism Compared with Aspirin in EINSTEIN CHOICE Study
17 Mar 2017 First dedicated outcome trials of empagliflozin in chronic heart failure initiated
17 Mar 2017 Selvita Announces First Patient Dosed in Phase I/II Clinical Trial of SEL24 in Acute Myeloid Leukemia
17 Mar 2017 AstraZeneca receives Complete Response Letter from US FDA for ZS-9 (sodium zirconium cyclosilicate) for hyperkalaemia
16 Mar 2017 Alkermes Initiates Phase 3 Gastrointestinal Tolerability Study of ALKS 8700 for Treatment of Multiple Sclerosis
16 Mar 2017 Asana BioSciences Announces FDA Acceptance of the IND Application for its Novel SYK-JAK Inhibitor for Evaluation in Atopic Dermatitis
15 Mar 2017 Vtesse Completes Enrollment of Phase 2b/3 Pivotal Clinical Trial of VTS-270 in Niemann-Pick Type C1 Disease

La Merie Biologics

FREE Weekly News Bulletin

2016 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing